The 2nd Annual Izon Science Research Symposium was held at Boston University from 21-22 October 2013. The event brought together researchers from a wide range of fields including: Particle-based Drug Delivery, Extracellular Vesicle Analysis, Virus Analysis, Nanotoxicology, Nanoeducation and Diagnostics Research, to discuss the latest developments with the TRPS technique.
“The qMicro applies Izon's design capability and nano-pore expertise to measurement at the micron scale. Micro-scale analysis is an easier problem and the result is a simple, compact and robust benchtop device. The qMicro offers accurate, repeatable and reliable measurement to a wide range of users in cell analysis,” says Hans van der Voorn, Executive Chairman of Izon Science Ltd.
The accuracy of particle characterization is one of the key elements to support any marketing application as all regulatory agencies expect manufacturers to have consistency, between batches, of particle size, concentration, charge and particle size distribution.
Professor Rinaldo Wellerson Pereira, Director of Postgraduate Studies in Science, Genomics, and Biotechnology at the Universidade Católica de Brasília and his team of researchers are looking at the effect of exercise on production of exosomes, which are cell-derived microvesicles thought to play a key role in intercellular signaling.
In the Grinstaff lab at Boston University, we have developed polymeric pH-responsive expansile nanoparticles (eNPs) for use as drug delivery vehicles. In particular, we use eNPs to facilitate the intracellular delivery of paclitaxel, a commonly used chemotherapeutic drug with poor aqueous solubility, as an improvement upon the traditional methods of delivery using Cremophor/ethanol. As eNPs are internalized by the cancer cells, they undergo a conformational change that causes them to swell with water, resulting in the release of their paclitaxel payload. In this manner, the encapsulation and controlled release of a poorly water soluble drug can be achieved.
Azaya Therapeutics Inc., an oncology company focused on developing more effective cancer treatments through its nanotechnology platform, announced the launch of a new division, AzayaLabs, a contract development and manufacturing organization (CDMO) providing chemical testing and liposomal manufacturing services to outside organizations. AzayaLabs leverages Azaya's twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. AzayaLabs offers laboratory services that can speed drug development and regulatory progress for pharmaceutical and medical device developers alike.
Researchers at Cardiff University Medical School, Wales Heart Institute are investigating vascular performance and differences between healthy and diseased blood vessels. Of particular interest to the group lead by Dr Philip James and Dr Aled Rees is the interaction between adipocytes and the vascular endothelium.
Izon Science is supporting the fast growing field of extracellular vesicle research with sponsorship of The International Society for Extracellular Vesicles (ISEV) 2013 Conference. Over 1,000 researchers are gathering in Boston to share knowledge on extracellular vesicles which can be used as biomarkers for early detection and diagnosis of diseases such as cancer and cardiovascular disease.
Leading scientific instrument manufacturer HORIBA Scientific will now sell and support the Izon qNano and qViro-X particle characterization products in France. The devices, which utilize innovative nanopore-based detection, are enabling leading researchers studying a range of nano- and micro-scale particles, including viruses, exosomes and drug delivery particles, to characterize their samples with a level of detail not previously available.
A new study from University of Queensland, and the National Measurement Institute (NMI) Australia highlights important differences between high resolution and low resolution techniques in particle sizing. The findings are significant in that they underlie the increasing importance placed on provision of data using high resolution techniques for getting nanomedicines into the clinic.